Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 706321 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 16 Dec 2020
At a glance
- Drugs BI 706321 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Dec 2020 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 28 Oct 2020 to 4 Dec 2020.
- 17 Nov 2020 Planned primary completion date changed from 28 Oct 2020 to 4 Dec 2020.